Bionomics Limited Files Definitive Proxy Statement

TL;DR

Bionomics DEF 14A filed. No fee. Standard shareholder meeting info.

AI Summary

Bionomics Limited filed a Definitive Proxy Statement (DEF 14A) on November 12, 2024, related to its annual meeting. The filing indicates no fee was required for this submission. The company is incorporated in C3 and its principal executive offices are located at 200 Greenhill Road, Eastwood SA 5063.

Why It Matters

This filing is a standard regulatory requirement for public companies, providing shareholders with information necessary to vote on company matters at their annual meeting.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would typically indicate risk.

Key Players & Entities

• BIONOMICS LIMITED/FI (company) — Registrant
• 200 GREENHILL ROAD (address) — Business and Mail Address
• EASTWOOD SA (location) — City and State
• 5063 (zip_code) — Business and Mail ZIP Code

FAQ

Key Financial Figures

• $400 — statement, have a value of less than US$400) on the Record Date will be regarded as
• $0.02 — holders of ADSs a cancellation fee of US$0.02 for each ADS cancelled in connection wi

Filing Documents

• ea0218389-def14a_bionomics.htm (DEF 14A) — 253KB
• image_001.jpg (GRAPHIC) — 3KB
• image_002.jpg (GRAPHIC) — 790KB
• image_003.jpg (GRAPHIC) — 499KB
• 0001213900-24-096782.txt ( ) — 2034KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL 19 WHERE YOU CAN FIND MORE INFORMATION 20 Where you can find more information about Bionomics 20 Incorporation by reference 20 PROPOSAL TO APPROVE THE SCHEME OF ARRANGEMENT 21 Required Vote and Board of Directors’ Recommendation 21 i SUMMARY The following summary highlights selected information contained elsewhere in this proxy statement and may not contain all the information that may be important to you. Accordingly, you are urged to read carefully this entire proxy statement, the information incorporated by reference and the other documents to which this proxy statement refers you in order for you to understand the matters being considered at the Scheme Meeting. The Companies Bionomics Bionomics is an Australian corporation. It is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). Bionomics’ ADSs have been trading Nasdaq Global Market (Nasdaq: BNOX) since 2021 and its ordinary shares ceased trading on the Australian Securities Exchange in August 2023. Neuphoria Neuphoria was recently incorporated in Delaware for purposes of re-domiciling our company to Delaware. Upon implementation of the Scheme, Neuphoria would become the successor issuer to Bionomics and the Neuphoria Shares would be listed on Nasdaq, replacing the Bionomics ADSs. Meeting of Bionomics Shareholders Purpose of the Scheme Meeting Bionomics shareholders are being asked to consider and vote upon a resolutio

View Full Filing

View this DEF 14A filing on SEC EDGAR